Could a diabetes drug stop heart failure before it starts?

NCT ID NCT06055452

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a daily pill called engagliflozin (a type of SGLT2 inhibitor) can improve heart function in people who have high blood pressure and early signs of heart failure but do not have diabetes. About 120 adults will receive either the drug or a placebo for 6 months. The main goal is to see if the drug reduces the size of the heart's left upper chamber, which is a marker of heart strain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder heart failure prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fuwai Hospital Chinese Academy of Medial Sciences, Shenzhen

    RECRUITING

    Shenzhen, Guangdong, 518038, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Fuwai Hospital, Chinese Academy of Medical Sciences

    RECRUITING

    Beijing, Beijing Municipality, 100037, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••